Daiichi Sankyo is committed to expanding scientific knowledge about edoxaban, as demonstrated through our research program evaluating its use in a broad range of cardiovascular conditions, patient types and clinical settings in atrial fibrillation (AF) and venous thromboembolism (VTE) designed to further build on the results of the pivotal ENGAGE AF-TIMI 48 and Hokusai-VTE studies.
The goal of EDOSURE is to generate new clinical and real-world-data regarding the use of edoxaban in AF and VTE populations, providing physicians and patients worldwide with greater treatment assurance.
More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, EDOSURE, which is comprised of more than 10 randomized, controlled trials, registries and non-interventional studies, including completed, ongoing and future research.
Edoxaban Studies in EDOSURE
RANDOMIZED-CONTROLLED CLINICAL TRIALS IN AF AND VTE
First Data Disclosure
Non valvular atrial fibrillation patients
Presented at AHA 2013
Presented at ESC 2013
AF patients undergoing transcatheter aortic valve implantation
Presented at ESC 2021
80 years or older Japanese AF patients who are ineligible for current OAC therapy
Presented at ESC 2020
Non valvular AF patients with history of stroke
AF patients with history of intracranial hemorrhage
REGISTRIES AND NON-RANDOMIZED CLINICAL STUDIES
Prolongation PREFER in AF PREvention oF thromboembolic events-European Registry in Atrial Fibrillation
All Nippon AF In Elderly registry in Japan to study NVAF in elderly patients aged 75 years and older
Edoxaban Management In diagnostic and Therapeutic procedures - AF/VTE
Venous Thromboembolism (VTE) in Cancer Patients; a Multicenter Prospective Registry in Japan
Multicenter study associated with KYU-shu to evaluate the efficacy and safety of edoxaban in patients with non-valvulaR Atrial fiBriLlation undergoing cathEter ablation
Real world ablation therapy with anticoagulants in management of atrial fibrillation in Japan